William Maughan
Stock Analyst at Canaccord Genuity
(2.97)
# 1,357
Out of 4,853 analysts
24
Total ratings
54.17%
Success rate
56.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $111.15 | +54.25% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $4.96 | +262.90% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $9.10 | +361.54% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $4.22 | +279.15% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $8.46 | +609.22% | 1 | Jul 6, 2022 | |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $111.15
Upside: +54.25%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $4.96
Upside: +262.90%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $9.10
Upside: +361.54%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $4.22
Upside: +279.15%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $8.46
Upside: +609.22%